Latest trial failure leaves OncoMed on the ropes as April slide nears 60%

19 April 2017

They say it never rains but it pours, and for OncoMed Pharmaceuticals (Nasdaq: OMED) it has been more thunder and lightning than April showers this month with three damaging setbacks.

The US biotech’s share price has now dropped to $3.74, a decline of nearly 60% from the $9.24 value of the beginning of April, and chief executive Paul Hastings has admitted that the company is now seriously considering its options and available resources.

"Based on the events of today and last week, we will be undertaking a comprehensive portfolio prioritization review immediately"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK